Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $10.30, for a total value of $228,886.60. Following the transaction, the chief operating officer now directly owns 22,222 shares in the company, valued at approximately $228,886.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Fennec Pharmaceuticals Trading Down 4.5 %

Shares of NASDAQ:FENC traded down $0.46 during trading on Wednesday, reaching $9.80. The company had a trading volume of 198,274 shares, compared to its average volume of 109,367. The stock’s fifty day moving average price is $10.10 and its 200 day moving average price is $9.31. Fennec Pharmaceuticals Inc has a fifty-two week low of $6.30 and a fifty-two week high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The company had revenue of $9.74 million during the quarter, compared to analysts’ expectations of $9.47 million. Equities analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the company. HC Wainwright lifted their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, April 4th. Craig Hallum boosted their target price on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Monday, March 18th. Finally, Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 18th.

Institutional Trading of Fennec Pharmaceuticals

Institutional investors have recently modified their holdings of the business. AIGH Capital Management LLC boosted its stake in shares of Fennec Pharmaceuticals by 6.9% in the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock valued at $2,805,000 after buying an additional 24,069 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Fennec Pharmaceuticals in the third quarter valued at approximately $50,000. Gendell Jeffrey L boosted its stake in shares of Fennec Pharmaceuticals by 0.9% in the third quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock valued at $2,148,000 after buying an additional 2,579 shares in the last quarter. HRT Financial LP purchased a new stake in Fennec Pharmaceuticals during the first quarter worth $454,000. Finally, Citigroup Inc. boosted its position in Fennec Pharmaceuticals by 10.3% during the first quarter. Citigroup Inc. now owns 18,590 shares of the company’s stock worth $151,000 after purchasing an additional 1,742 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.